Browse PARP1

Summary
SymbolPARP1
Namepoly (ADP-ribose) polymerase 1
Aliases PPOL; ADPRT; ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase); poly (ADP-ribose) polymerase famil ......
Chromosomal Location1q41-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Nucleus, nucleolus Note=Localizes at sites of DNA damage.
Domain PF00533 BRCA1 C Terminus (BRCT) domain
PF08063 PADR1 (NUC008) domain
PF00644 Poly(ADP-ribose) polymerase catalytic domain
PF02877 Poly(ADP-ribose) polymerase
PF05406 WGR domain
PF00645 Poly(ADP-ribose) polymerase and DNA-Ligase Zn-finger region
Function

Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks (PubMed:17177976, PubMed:18172500, PubMed:19344625, PubMed:19661379, PubMed:23230272). Mediates the poly(ADP-ribosyl)ation of APLF and CHFR (PubMed:17396150). Positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. With EEF1A1 and TXK, forms a complex that acts as a T-helper 1 (Th1) cell-specific transcription factor and binds the promoter of IFN-gamma to directly regulate its transcription, and is thus involved importantly in Th1 cytokine production (PubMed:17177976). Required for PARP9 and DTX3L recruitment to DNA damage sites (PubMed:23230272). PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites (PubMed:23230272). Mediates serine ADP-ribosylation of target proteins following interaction with HPF1; HPF1 conferring serine specificity (PubMed:28190768). Mediates the poly(ADP-ribosyl)ation of histones in a HPF1-dependent manner (PubMed:27067600). Involved in the synthesis of ATP in the nucleus, together with NMNAT1, PARG and NUDT5 (PubMed:27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed:27257257).

> Gene Ontology
 
Biological Process GO:0000002 mitochondrial genome maintenance
GO:0000715 nucleotide-excision repair, DNA damage recognition
GO:0000717 nucleotide-excision repair, DNA duplex unwinding
GO:0000723 telomere maintenance
GO:0000724 double-strand break repair via homologous recombination
GO:0000725 recombinational repair
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0003012 muscle system process
GO:0003254 regulation of membrane depolarization
GO:0003300 cardiac muscle hypertrophy
GO:0006260 DNA replication
GO:0006261 DNA-dependent DNA replication
GO:0006266 DNA ligation
GO:0006271 DNA strand elongation involved in DNA replication
GO:0006273 lagging strand elongation
GO:0006289 nucleotide-excision repair
GO:0006293 nucleotide-excision repair, preincision complex stabilization
GO:0006294 nucleotide-excision repair, preincision complex assembly
GO:0006295 nucleotide-excision repair, DNA incision, 3'-to lesion
GO:0006296 nucleotide-excision repair, DNA incision, 5'-to lesion
GO:0006302 double-strand break repair
GO:0006304 DNA modification
GO:0006305 DNA alkylation
GO:0006306 DNA methylation
GO:0006310 DNA recombination
GO:0006471 protein ADP-ribosylation
GO:0006486 protein glycosylation
GO:0006606 protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0006979 response to oxidative stress
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007183 SMAD protein complex assembly
GO:0007184 SMAD protein import into nucleus
GO:0008631 intrinsic apoptotic signaling pathway in response to oxidative stress
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009123 nucleoside monophosphate metabolic process
GO:0009126 purine nucleoside monophosphate metabolic process
GO:0009141 nucleoside triphosphate metabolic process
GO:0009144 purine nucleoside triphosphate metabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009161 ribonucleoside monophosphate metabolic process
GO:0009167 purine ribonucleoside monophosphate metabolic process
GO:0009199 ribonucleoside triphosphate metabolic process
GO:0009205 purine ribonucleoside triphosphate metabolic process
GO:0009314 response to radiation
GO:0009755 hormone-mediated signaling pathway
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010043 response to zinc ion
GO:0010212 response to ionizing radiation
GO:0010332 response to gamma radiation
GO:0010611 regulation of cardiac muscle hypertrophy
GO:0010613 positive regulation of cardiac muscle hypertrophy
GO:0010639 negative regulation of organelle organization
GO:0010833 telomere maintenance via telomere lengthening
GO:0010990 regulation of SMAD protein complex assembly
GO:0014742 positive regulation of muscle hypertrophy
GO:0014743 regulation of muscle hypertrophy
GO:0014896 muscle hypertrophy
GO:0014897 striated muscle hypertrophy
GO:0016485 protein processing
GO:0016540 protein autoprocessing
GO:0016925 protein sumoylation
GO:0017038 protein import
GO:0018205 peptidyl-lysine modification
GO:0022616 DNA strand elongation
GO:0023019 signal transduction involved in regulation of gene expression
GO:0030099 myeloid cell differentiation
GO:0030225 macrophage differentiation
GO:0030518 intracellular steroid hormone receptor signaling pathway
GO:0030520 intracellular estrogen receptor signaling pathway
GO:0030522 intracellular receptor signaling pathway
GO:0031334 positive regulation of protein complex assembly
GO:0031960 response to corticosteroid
GO:0032042 mitochondrial DNA metabolic process
GO:0032200 telomere organization
GO:0032204 regulation of telomere maintenance
GO:0032205 negative regulation of telomere maintenance
GO:0032259 methylation
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032392 DNA geometric change
GO:0032508 DNA duplex unwinding
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0033044 regulation of chromosome organization
GO:0033143 regulation of intracellular steroid hormone receptor signaling pathway
GO:0033145 positive regulation of intracellular steroid hormone receptor signaling pathway
GO:0033146 regulation of intracellular estrogen receptor signaling pathway
GO:0033148 positive regulation of intracellular estrogen receptor signaling pathway
GO:0033157 regulation of intracellular protein transport
GO:0033683 nucleotide-excision repair, DNA incision
GO:0034504 protein localization to nucleus
GO:0034599 cellular response to oxidative stress
GO:0036446 myofibroblast differentiation
GO:0036473 cell death in response to oxidative stress
GO:0036475 neuron death in response to oxidative stress
GO:0036480 neuron intrinsic apoptotic signaling pathway in response to oxidative stress
GO:0042278 purine nucleoside metabolic process
GO:0042306 regulation of protein import into nucleus
GO:0042307 positive regulation of protein import into nucleus
GO:0042391 regulation of membrane potential
GO:0042769 DNA damage response, detection of DNA damage
GO:0043254 regulation of protein complex assembly
GO:0043388 positive regulation of DNA binding
GO:0043401 steroid hormone mediated signaling pathway
GO:0043413 macromolecule glycosylation
GO:0043414 macromolecule methylation
GO:0043434 response to peptide hormone
GO:0043500 muscle adaptation
GO:0043502 regulation of muscle adaptation
GO:0043504 mitochondrial DNA repair
GO:0043523 regulation of neuron apoptotic process
GO:0044030 regulation of DNA methylation
GO:0044057 regulation of system process
GO:0044089 positive regulation of cellular component biogenesis
GO:0044728 DNA methylation or demethylation
GO:0044744 protein targeting to nucleus
GO:0046034 ATP metabolic process
GO:0046128 purine ribonucleoside metabolic process
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0048545 response to steroid hormone
GO:0051052 regulation of DNA metabolic process
GO:0051053 negative regulation of DNA metabolic process
GO:0051098 regulation of binding
GO:0051099 positive regulation of binding
GO:0051101 regulation of DNA binding
GO:0051103 DNA ligation involved in DNA repair
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051222 positive regulation of protein transport
GO:0051385 response to mineralocorticoid
GO:0051402 neuron apoptotic process
GO:0051604 protein maturation
GO:0051881 regulation of mitochondrial membrane potential
GO:0051882 mitochondrial depolarization
GO:0051899 membrane depolarization
GO:0051900 regulation of mitochondrial depolarization
GO:0051901 positive regulation of mitochondrial depolarization
GO:0060249 anatomical structure homeostasis
GO:0060390 regulation of SMAD protein import into nucleus
GO:0060391 positive regulation of SMAD protein import into nucleus
GO:0065004 protein-DNA complex assembly
GO:0070085 glycosylation
GO:0070212 protein poly-ADP-ribosylation
GO:0070911 global genome nucleotide-excision repair
GO:0070997 neuron death
GO:0071103 DNA conformation change
GO:0071241 cellular response to inorganic substance
GO:0071248 cellular response to metal ion
GO:0071294 cellular response to zinc ion
GO:0071375 cellular response to peptide hormone stimulus
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071824 protein-DNA complex subunit organization
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090257 regulation of muscle system process
GO:0090305 nucleic acid phosphodiester bond hydrolysis
GO:0090316 positive regulation of intracellular protein transport
GO:0097193 intrinsic apoptotic signaling pathway
GO:1900180 regulation of protein localization to nucleus
GO:1900182 positive regulation of protein localization to nucleus
GO:1900407 regulation of cellular response to oxidative stress
GO:1901214 regulation of neuron death
GO:1901216 positive regulation of neuron death
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1901654 response to ketone
GO:1901657 glycosyl compound metabolic process
GO:1902175 regulation of oxidative stress-induced intrinsic apoptotic signaling pathway
GO:1902593 single-organism nuclear import
GO:1902882 regulation of response to oxidative stress
GO:1903201 regulation of oxidative stress-induced cell death
GO:1903203 regulation of oxidative stress-induced neuron death
GO:1903376 regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway
GO:1903533 regulation of protein targeting
GO:1903829 positive regulation of cellular protein localization
GO:1904044 response to aldosterone
GO:1904181 positive regulation of membrane depolarization
GO:1904356 regulation of telomere maintenance via telomere lengthening
GO:1904357 negative regulation of telomere maintenance via telomere lengthening
GO:1904589 regulation of protein import
GO:1904591 positive regulation of protein import
GO:1904645 response to beta-amyloid
GO:1904646 cellular response to beta-amyloid
GO:1904760 regulation of myofibroblast differentiation
GO:1904762 positive regulation of myofibroblast differentiation
GO:1904951 positive regulation of establishment of protein localization
GO:1990267 response to transition metal nanoparticle
GO:1990966 ATP generation from poly-ADP-D-ribose
GO:2000021 regulation of ion homeostasis
GO:2000677 regulation of transcription regulatory region DNA binding
GO:2000679 positive regulation of transcription regulatory region DNA binding
GO:2001233 regulation of apoptotic signaling pathway
GO:2001242 regulation of intrinsic apoptotic signaling pathway
GO:2001251 negative regulation of chromosome organization
Molecular Function GO:0003909 DNA ligase activity
GO:0003910 DNA ligase (ATP) activity
GO:0003950 NAD+ ADP-ribosyltransferase activity
GO:0008134 transcription factor binding
GO:0016757 transferase activity, transferring glycosyl groups
GO:0016763 transferase activity, transferring pentosyl groups
GO:0016874 ligase activity
GO:0016886 ligase activity, forming phosphoric ester bonds
GO:0030331 estrogen receptor binding
GO:0035257 nuclear hormone receptor binding
GO:0035258 steroid hormone receptor binding
GO:0042826 histone deacetylase binding
GO:0046332 SMAD binding
GO:0047485 protein N-terminus binding
GO:0048037 cofactor binding
GO:0050662 coenzyme binding
GO:0051287 NAD binding
GO:0051427 hormone receptor binding
GO:0070412 R-SMAD binding
Cellular Component GO:0000781 chromosome, telomeric region
GO:0000784 nuclear chromosome, telomeric region
GO:0005635 nuclear envelope
GO:0005667 transcription factor complex
GO:0044454 nuclear chromosome part
GO:0098687 chromosomal region
> KEGG and Reactome Pathway
 
KEGG hsa03410 Base excision repair
hsa04064 NF-kappa B signaling pathway
hsa04210 Apoptosis
Reactome R-HSA-73884: Base Excision Repair
R-HSA-5696394: DNA Damage Recognition in GG-NER
R-HSA-5693532: DNA Double-Strand Break Repair
R-HSA-73894: DNA Repair
R-HSA-2173795: Downregulation of SMAD2/3
R-HSA-5696400: Dual Incision in GG-NER
R-HSA-5696395: Formation of Incision Complex in GG-NER
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-5696399: Global Genome Nucleotide Excision Repair (GG-NER)
R-HSA-5685939: HDR through MMEJ (alt-NHEJ)
R-HSA-5693538: Homology Directed Repair
R-HSA-392499: Metabolism of proteins
R-HSA-5696398: Nucleotide Excision Repair
R-HSA-110362: POLB-Dependent Long Patch Base Excision Repair
R-HSA-597592: Post-translational protein modification
R-HSA-110373: Resolution of AP sites via the multiple-nucleotide patch replacement pathway
R-HSA-73933: Resolution of Abasic Sites (AP sites)
R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins
R-HSA-2990846: SUMOylation
R-HSA-3108214: SUMOylation of DNA damage response and repair proteins
R-HSA-162582: Signal Transduction
R-HSA-170834: Signaling by TGF-beta Receptor Complex
R-HSA-2173793: Transcriptional activity of SMAD2/SMAD3
Summary
SymbolPARP1
Namepoly (ADP-ribose) polymerase 1
Aliases PPOL; ADPRT; ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase); poly (ADP-ribose) polymerase famil ......
Chromosomal Location1q41-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PARP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PARP1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28167507Breast CarcinomaPromote immunity (T cell function)PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
26138335Breast CarcinomaInhibit immunityThese results demonstrate that CTLA-4 blockade combined with PARP inhibition induces protective antitumor immunity and significant survival benefit in the BRCA1(-) tumor model, and support clinical testing of this regimen to improve outcomes for women with hereditary ovarian cancer.
Summary
SymbolPARP1
Namepoly (ADP-ribose) polymerase 1
Aliases PPOL; ADPRT; ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase); poly (ADP-ribose) polymerase famil ......
Chromosomal Location1q41-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PARP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPARP1
Namepoly (ADP-ribose) polymerase 1
Aliases PPOL; ADPRT; ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase); poly (ADP-ribose) polymerase famil ......
Chromosomal Location1q41-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PARP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2560.326
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6510.805
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0410.984
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2920.33
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3460.883
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2280.942
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2530.568
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1020.962
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6830.771
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2320.888
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5720.821
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2180.00198
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PARP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolPARP1
Namepoly (ADP-ribose) polymerase 1
Aliases PPOL; ADPRT; ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase); poly (ADP-ribose) polymerase famil ......
Chromosomal Location1q41-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PARP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPARP1
Namepoly (ADP-ribose) polymerase 1
Aliases PPOL; ADPRT; ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase); poly (ADP-ribose) polymerase famil ......
Chromosomal Location1q41-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PARP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PARP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPARP1
Namepoly (ADP-ribose) polymerase 1
Aliases PPOL; ADPRT; ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase); poly (ADP-ribose) polymerase famil ......
Chromosomal Location1q41-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PARP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPARP1
Namepoly (ADP-ribose) polymerase 1
Aliases PPOL; ADPRT; ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase); poly (ADP-ribose) polymerase famil ......
Chromosomal Location1q41-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PARP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPARP1
Namepoly (ADP-ribose) polymerase 1
Aliases PPOL; ADPRT; ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase); poly (ADP-ribose) polymerase famil ......
Chromosomal Location1q41-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PARP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPARP1
Namepoly (ADP-ribose) polymerase 1
Aliases PPOL; ADPRT; ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase); poly (ADP-ribose) polymerase famil ......
Chromosomal Location1q41-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PARP1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PARP1.
ID Name Drug Type Targets #Targets
DB00277TheophyllineSmall MoleculeADORA1, ADORA2A, ADORA2B, CPNE1, HDAC2, HM13, NOMO1, PARP1, PDE3A, ......14
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119
DB02498Carba-Nicotinamide-Adenine-DinucleotideSmall MoleculePARP11
DB02690NU1025Small MoleculePARP11
DB02701NicotinamideSmall MoleculeBST1, LDHA, PARP1, SIRT54
DB030722-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-QuinazolinoneSmall MoleculePARP11
DB030733-MethoxybenzamideSmall MoleculePARP11
DB035092-(4-Chlorophenyl)-5-QuinoxalinecarboxamideSmall MoleculePARP11
DB037223,4-Dihydro-5-Methyl-IsoquinolinoneSmall MoleculePARP11
DB040102-(3'-Methoxyphenyl) Benzimidazole-4-CarboxamideSmall MoleculePARP11
DB070966-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONESmall MoleculePARP11
DB07232VeliparibSmall MoleculePARP1, PARP22
DB07330trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidiniumSmall MoleculePARP11
DB077875-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONESmall MoleculePARP11
DB09074OlaparibSmall MoleculePARP1, PARP2, PARP33
DB11793NiraparibSmall MoleculePARP1, PARP22
DB12332RucaparibSmall MoleculePARP1, PARP2, PARP33
DB13877IniparibSmall MoleculePARP11